Your browser doesn't support javascript.
An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic.
Jamwal, Sumit; Gautam, Akash; Elsworth, John; Kumar, Mandeep; Chawla, Rakesh; Kumar, Puneet.
  • Jamwal S; Department of Psychiatry, Yale School of Medicine, Yale University, New Haven, CT 06511, USA.
  • Gautam A; Center for Neural and Cognitive Sciences, University of Hyderabad, Hyderabad 500046, India.
  • Elsworth J; Department of Psychiatry, Yale School of Medicine, Yale University, New Haven, CT 06511, USA.
  • Kumar M; University of Genoa, Department of Pharmacology and Toxicology, Viale Cembrano 4, Genoa, Italy.
  • Chawla R; University Institute of Pharmaceutical Sciences & Research, Baba Farid University of Health Sciences, Faridkot, Punjab, India.
  • Kumar P; Department of Pharmacology, Central University of Punjab, Bathinda 151001, India. Electronic address: puneet.bansal@cup.edu.in.
Life Sci ; 257: 118105, 2020 Sep 15.
Article in English | MEDLINE | ID: covidwho-654811
ABSTRACT
Coronavirus disease 2019 (COVID-19) is an unprecedented disease caused by highly pathogenic SARS-CoV-2 and characterized by extreme respiratory deterrence, pneumonia and immune damage. The phylogenetic analysis demonstrated the sequence similarity of SARS-CoV-2 with other SARS-like bat viruses. The primary source and intermediate host are not yet confirmed, although transmission from human to human is universally confirmed. The new SARS-CoV-2 virus reaches cells via ACE-2 and subsequently down-regulates ACE-2, leaving angiotensin II unbalanced in affected organs primarily in the lungs, heart, brain, and kidneys. As reported recently, numerous secondary complications i.e., neurological, nephrological, cardiovascular, gastrointestinal, immune, and hepatic complications, are associated with COVID-19 infection along with prominent respiratory disease including pneumonia. Extensive research work on recently discovered SARS-CoV-2 is in the pipeline to clarify pathogenic mechanisms, epidemiological features, and identify new drug targets that will lead to the development of successful strategies for prevention and treatment. There are currently no appropriate scientifically approved vaccines/drugs for COVID-19. Nonetheless, few broad-spectrum antiviral drugs, azithromycin were tested against COVID-19 in clinical trials, and finally, FDA approved emergency use of remdesivir in hospitalized COVID-19 patients. Additionally, administration of convalescent plasma obtained from recovered COVID-19 patients to infected COVID-19 patients reduces the viral burden via immunomodulation. This review analysis therefore concentrates primarily on recent discoveries related to COVID-19 pathogenesis along with a full description of the structure, genome, and secondary complication associated with SARS-CoV-2. Finally, a short and brief clinical update has been provided concerning the development of therapeutic medications and vaccines to counter COVID-19.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Life Sci Year: 2020 Document Type: Article Affiliation country: J.lfs.2020.118105

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Betacoronavirus Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Life Sci Year: 2020 Document Type: Article Affiliation country: J.lfs.2020.118105